By Andrew Silver SHANGHAI, Nov 12 (Reuters) – Eli Lilly on Thursday became the first drugmaker to have a GLP-1 weight-loss pill approved in China, giving it an edge over Danish rival Novo Nordisk in
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)